Notice 21 Aug 2025 public meeting, pharmaceuticals, fda, financial transparency, user fee programs

💊Public Meeting on Financial Transparency for Prescription Drug Fees

The Food and Drug Administration (FDA or the Agency) is announcing the following public meeting entitled "Financial Transparency and Efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments." The topic to be discussed is the financial transparency and efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments.

Learn More